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Background. Amiodarone is an effective and widely used antiarrhythmic drug with many possible adverse effects including hypercholesterolaemia and hepatotoxicity.
Objective. Our aim was to evaluate how long-term amiodarone treatment affects cholesterol metabolism.
Methods. The study population consisted of 56 cardiac patients, of whom 20 were on amiodarone (amiodarone + group) and 36 did not use the drug (amiodarone À group). We also studied a control group of 124 individuals selected randomly from the population. Cholesterol metabolism was evaluated by analysis of serum noncholesterol sterols by gas-liquid chromatography and gas chromatography-mass spectrometry.
Results. Comparisons of serum lipids and noncholesterol sterols across the three groups showed increased serum triglyceride in users of amiodarone but no statistically significant group differences in total, LDL or HDL cholesterol or serum proprotein convertase subtilisin/kexin type 9 concentrations. Nor did the groups differ in the ratios of cholestanol or plant sterols to cholesterol in serum, suggesting that cholesterol absorption was unaltered. However, all users of amiodarone had very markedly elevated serum desmosterol concentrations: the desmosterol-to-cholesterol ratio (10 2 9 lmol mmol À1 ) averaged 1030.7 AE 115.7 (mean AE SE) in the amiodarone + group versus 82.7 AE 3.4 and 75.9 AE 1.4 in the amiodarone À and the population control groups (P < 0.001), respectively.
Conclusion. Use of amiodarone was associated with on average 12-fold serum desmosterol concentrations compared with the control groups. This observation is fully novel and suggests that amiodarone interferes with the conversion of desmosterol to cholesterol in the cholesterol synthesis pathway. Whether accumulation of desmosterol
Introduction
Amiodarone, an iodinated derivative of benzofuran, is an antiarrhythmic drug widely used to suppress atrial and ventricular tachyarrhythmias. It is effective but has many potential adverse effects including corneal deposits and lens opacities, liver and lung injury, abnormalities of thyroid function, skin changes, and peripheral and optic neuropathy [1] . It has also been reported to increase serum total and LDL cholesterol concentrations in a dosedependent manner independently of the thyroid function [2] [3] [4] [5] [6] . Based on animal experiments, this may be due to amiodarone reducing the number of hepatic LDL receptors [7] . As the benzofuran ring of amiodarone is lipophilic, the drug accumulates easily in cells where it may cause mitochondrial damage and structural and functional disturbances in the late endosomes and lysosomes [8] [9] [10] . Thus, increased amounts of free cholesterol and phospholipids may accumulate in the cells as a result of the amiodarone-induced 'lipid traffic jam' [9, 10] . In the liver, amiodarone can cause nonalcoholic steatohepatitis (NASH) [8] , the severe form of nonalcoholic fatty liver disease (NAFLD) including inflammation with fat accumulation. On the other hand, NAFLD itself interferes with cholesterol metabolism so that cholesterol synthesis is upregulated, cholesterol absorption efficiency is downregulated and free cholesterol accumulates in the liver [11, 12] . One of the cholesterol precursors, in particular, desmosterol, has been demonstrated to build up in serum and liver in NASH [13] . Its hepatic and serum concentrations correlate with the severity of steatosis and inflammation in the liver, suggesting that desmosterol may have a role in the pathogenesis of NASH [13] . We set out to study whether and how cholesterol metabolism is altered in subjects on long-term amiodarone treatment. In particular we wanted to see whether serum desmosterol levels are affected by amiodarone. Thus, we determined serum noncholesterol sterols including the cholesterol precursors squalene, lanosterol, D
8
-cholestenol (5a-cholest-8-en-3b-ol), desmosterol and lathosterol, that are biomarkers of cholesterol synthesis, and cholestanol, campesterol, sitosterol and avenasterol, biomarkers of cholesterol absorption [14] [15] [16] [17] [18] [19] , in cardiac patients with and without long-term amiodarone treatment and in a control group of age-adjusted random population sample.
Materials and methods

Study population
The study population consisted of 56 consecutive patients, 40 women and 16 men with a mean age of 52 years, who had histologically verified myocardial inflammatory disease (MID). Seven patients had giant cell myocarditis (GCM) and 49 had cardiac sarcoidosis (CS). Of them, 20 individuals were on long-term amiodarone treatment for ventricular arrhythmias. We chose this population due to their lack of other accompanying metabolic diseases and their frequent need for antiarrhythmic medication. All diagnoses of MID were made after the year 2008 using the criteria detailed in our previous works [20] [21] [22] . In brief, diagnosis of GCM required the presence of a widespread myocardial inflammatory infiltrates with multinucleated giant cells in association with myocyte necrosis and eosinophils [20, 21] . The diagnosis of CS in turn was based on the presence of noncaseating granulomatous inflammation either in an endomyocardial biopsy or in an extracardiac tissue sample; in the latter case, the diagnosis also required the presence of findings compatible with myocardial involvement in cardiac imaging [21, 22] . Histologic verification was based on myocardial samples in seven of seven patients with GCM and in 24 of 49 patients with CS. In the remaining 25 CS patients, the presence of sarcoidosis had been confirmed from biopsies of lymph nodes (n = 19) or extracardiac organs (n = 6). The clinical data of these patients including demographics, medical history and symptoms, laboratory tests, electrocardiogram, imaging results, and histopathological analyses of biopsy material were retrospectively reviewed and analysed in detail for this study. The patients were followed up regularly as ambulatory outpatients in our hospital. Any immunosuppressive medication had to remain unchanged for 1 month before the study.
The control group consisted of 124 age-matched subjects (61 women, 63 men) selected randomly from the Finnish Population Register and living in our area. The use of lipid lowering medication was an exclusion criterion for both the MID patients and control subjects.
All subjects gave their written informed consent. The study was performed according to the principles of the Declaration of Helsinki. The Ethics Committee for the Department of Medicine, Hospital District of Helsinki and Uusimaa, approved the study protocol.
Study design
Fasting blood samples were drawn after a 12-h fast. All subjects of the study population were weighed, height was measured, body mass index (BMI) was calculated as weight (kg)/height (m) 2 and a history of previous diseases and current drug treatment was recorded. All subjects were studied whilst on their normal habitual diet.
Methods
Plasma glucose, thyreotropin, free thyroxine, highsensitive C-reactive protein (hsCRP), troponin T, the prohormone of brain natriuretic peptide (preBNP) and serum alanine aminotransferase (ALAT) were analysed in the MID patients with routine methods of the Central Laboratory of Helsinki University Central Hospital (HUSLAB). Serum total, LDL and HDL cholesterol, as well as serum triglycerides, were measured in the whole study population using an automated analyzer (HUSLAB).
Serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concentration, which regulates LDL cholesterol metabolism by targeting LDL receptors for degradation, was analysed in the MID patients with the Quantikine â Elisa Immunoassay using a monoclonal capture antibody and a polyclonal detector antiserum specific for human PCSK9 (www.rndsystems.com/pdf/DPC900.pdf). According to the manufacturer, the intra-and interassay CV% varied from 4.1 to 6.5. The range of serum concentrations in a random population sample is 177-460 ng mL
À1
, with a mean AE SD of 313 AE 71 ng mL
. Serum cholesterol and noncholesterol sterols and squalene were quantified by capillary gas-liquid chromatography (GLC) with flame ionization detection and using a 50-m capillary column (Ultra 2; Agilent Technologies, Wilmington, DE, USA) with 5a-cholestane as the internal standard [23] . Gas chromatography-mass spectrometry (GC-MS) was used to further analyse and confirm the identity of the peaks in the GLC spectra. Spectra of the peaks of specific interest from the sample were compared with the library MS spectra obtained from the Wiley 7N library (Wiley Registry of Mass Spectral Data, 7th Ed) and obtained by the Enhanced ChemStation MSD software (Agilent Technologies).
The concentrations of the noncholesterol sterols were expressed as ratios to cholesterol (10 2 9 lmol mmol À1 of cholesterol) by adjusting the noncholesterol sterol concentrations to the cholesterol value in the same GLC run, and multiplying the ratio by 10 2 .
Statistics
Statistical analyses were performed with SPSS for Windows 22.0 (SPSS, Chicago, IL, USA). The normality and homogeneity of variance assumptions were checked before further analyses. Comparison of continuous variables between groups was performed by analysis of variance followed by independent samples t-test or Mann-Whitney test if the normality and homogeneity of variance were not reached with logarithmic transformation. Noncontinuous variables were tested with Chi-squared or with Fisher's exact test. Spearman's correlation coefficients were calculated. A P-value of <0.05 was considered statistically significant. The results are expressed as mean AE SE. Table 1 summarizes the key characteristics of the MID groups with and without long-term amiodarone treatment and shows also selected characteristics for the control population sample. The mean duration from diagnosis to the time of our study was 29 months (range 4-96 months) in the amiodarone + group and 30 months (range 4-96 months) in the amiodarone À group. As Table 1 shows, the patient characteristics did not differ statistically significantly between the two MID groups except that plasma thyreotropin and free thyroxine as well as serum ALAT were slightly higher in patients on amiodarone. All thyreotropin and free thyroxine values were within the reference range, however. Three MID patients had diabetes, one patient in the amiodarone + group and two in the comparator group; all were under good glycaemic control. The control population sample was well matched for age with the MID patients, but there was a difference in gender distribution with a female preponderance amongst the patient groups (Table 1 ). In patients on amiodarone, the daily dose of the drug ranged from 100 to 200 mg day À1 and averaged 180 AE 9 mg day À1 at the time of our study.
Results
Study population
Lipids, PCSK9 and noncholesterol sterols
Serum and lipoprotein cholesterol concentrations did not differ between the amiodarone + and amiodarone À groups (Table 2) . Serum triglyceride concentrations were higher in the amiodarone + than in the amiodarone À and the control groups. LDL cholesterol concentrations were lower in the amiodarone + and amiodarone À groups compared with the population controls. Serum and lipoprotein cholesterol and serum triglyceride concentrations did not differ between men and women in any of the groups except for HDL cholesterol, which was higher in women than in men in all three groups (P < 0.05 for all).
Serum PCSK9 concentrations and the noncholesterol sterols were independent of sex, immunosuppressive treatment and use of beta blockers in either MID group. The PCSK9 concentrations were also comparable in patients with and without amiodarone ( Table 2) .
Of the cholesterol precursors (Fig. 1) , serum squalene, lanosterol and lathosterol were comparable in the amiodarone + and amiodarone À groups ( Table 2 ). The D
8
-cholestenol-to-cholesterol ratio, instead, was on average 2.7 times higher in patients on amiodarone than in those not using the drug. The difference in plasma desmosterol was still much more marked with the mean desmosterol-to-cholesterol ratio being 12-fold in the former group compared with the latter (P < 0.001; Table 2 ). The GC-MS analysis confirmed the purity of desmosterol (Fig. 2) . There even was no overlap in the individual desmosterol concentrations which were in the range 13.0-110.6 lmol L ) in the amiodarone À group (Fig. 3) . In users of amiodarone, the desmosterolto-cholesterol ratio also correlated with the current daily dose of the drug (r = 0.559, P < 0.01). In one patient, we had access to serum samples taken before and after starting amiodarone and could directly confirm the increase of desmosterol accompanying the use of the drug (Fig. 4) . Cholestanol and the plant sterols campesterol, sitosterol and avenasterol were comparable in the two MID groups (NS).
Compared to the population control subjects, the D 8 -cholestenol and desmosterol ratios to cholesterol were statistically significantly higher in the MID patients on amiodarone (Table 2) . Table 2 shows also that squalene and lathosterol levels were lower and cholestanol, campesterol, and sitosterol were higher in both MID groups compared with the control group.
In the amiodarone + group, none of the cholesterol synthesis markers correlated with the cholesterol absorption markers (e.g. cholestanol-lathosterol, r = À0.012, NS). In the amiodarone À group, all precursor sterols and absorption markers were inversely interrelated (e.g. cholestanol-lathosterol, 
, males <194 ng L À1 ; alanine aminotransferase females <35 U L À1 , males <50 U L À1 ; ejection fraction ≥50%. *P < 0.05 from the amiodarone À group. **P < 0.05 from the control subjects. r = À0.432, P < 0.001), suggesting that cholesterol homeostasis was intact in the amiodarone À but disrupted in the amiodarone + group. Serum desmosterol-to-cholesterol ratio did not correlate with ALAT in either group.
Discussion
The present study shows that circulating desmosterol concentrations are consistently and very markedly elevated in users of amiodarone. The biomarkers of cholesterol absorption and the PCSK9 metabolism, instead, were independent of amiodarone therapy. Serum triglycerides were elevated in users of amiodarone, but in contrast to earlier reports [2] [3] [4] [5] [6] , serum and LDL cholesterol were unrelated to the use of this drug. According to our sterol data, the most likely explanation for accumulation of desmosterol is that amiodarone interferes with the conversion of desmosterol to cholesterol.
To have a cardiac study population that is homogeneous and where amiodarone use is frequent, we focused on patients with biopsy-verified MID, mainly CS. In an earlier study on patients with Mean AE SE. a 10 2 9 lmol mmol À1 of cholesterol. *P < 0.05 from the amiodarone À group. **P < 0.05 from the control subjects. CS, biomarkers of cholesterol synthesis were low and those of cholesterol absorption efficiency high compared to control subjects [22] . The present study confirmed this finding and demonstrated also that the subjects with GCM shared the same profile of cholesterol metabolism. According to laboratory tests, clinical evaluation and echocardiography, the myocardial disease was in a stable phase in all patients, being either inactive or responding to treatment even in those with GCM. It is unlikely that the concomitant immunosuppressive treatment influenced our main results as there was no difference in serum lipid or noncholesterol sterol levels between patients with or without immunosuppression or between different immunosuppressants.
In the cholesterol synthesis pathway, lanosterol is metabolized to cholesterol either by the Bloch unsaturated or the Kandutsch-Russell saturated side chain pathways [24, 25] (Fig. 1) . In the Bloch pathway, cytochrome P450 enzyme CYP51A1 converts lanosterol to D 8,24 -dimethylsterol, and after several intermediates, desmosterol is formed as the final intermediate and converted to cholesterol by 24-dehydrocholesterol reductase (DHCR24). In the Kandutsch-Russell pathway, DHCR24 converts lanosterol to dihydrolanosterol followed by the formation of D
8
-cholestenol and lathosterol downstream in the pathway. Finally, 7-dehydrocholesterol is converted to cholesterol. Thus, DHCR24 is involved in the end of the Bloch pathway and at the entry to the Kandutsch-Russell pathway and, in fact, at any step along the Bloch pathway [26, 27] . However, the hierarchical regulation of enzyme activity on different substrates is unknown [28] . The accumulation of desmosterol in serum during amiodarone treatment suggests that amiodarone inhibits the DHCR24 enzyme activity for formation of cholesterol from desmosterol but not at other sites of the pathway.
The experience with triparanol
, a hypocholesterolaemic drug developed in the 1960s, illuminates the effects of inhibiting the conversion of desmosterol to cholesterol [29] . Triparanol and amiodarone belong to the same group of cationic amphiphilic drugs which in general cause phospholipid and cholesterol accumulation in cells and damage mitochondria and late endosomes [9, 10] . Triparanol was withdrawn from the market after a few years of use because of frequent dermal and ocular side effects, mainly cataracts. The drug increased serum and tissue desmosterol concentrations from practically undetectable ), even up to 15.5 mg L À1 (4.03 mmol L À1 ), and raised the proportion of serum desmosterol from 0.1% to 27% of the total serum sterols [29] . Concomitantly, serum cholesterol decreased by 34% [29] . In our amiodarone + group, the highest desmosterol concentration was 0.42 mg L À1 (0.11 mmol L
À1
), and the proportion of desmosterol was 1.0% of the total serum sterols, which figures suggest that desmosterol accumulation was much less with amiodarone in our patients than in earlier studies with triparanol. It seems likely that amiodarone blocks the DHCR24 activity only partially, which could also explain the lack of group difference in serum cholesterol concentration (i.e. decrease by amiodarone) in our study.
Nine subjects with missense mutations in the DHCR24 gene have been described causing an extremely rare disease called desmosterolosis [30] [31] [32] [33] [34] [35] . This disease is characterized by defective activity of the DHCR24 enzyme and elevated serum and tissue desmosterol as well as several congenital defects and failure to thrive. Serum desmosterol varied from 0.45 to 1.26 mg L À1 (0.12 to 0.33 mmol L À1 ) in these patients, but, interestingly, serum cholesterol concentrations were within normal limits [32] [33] [34] . In one study [33] , serum lathosterol and 7-dehydrocholesterol were also quantitated and found to be within the reference range. The normal serum cholesterol concentrations suggest that the missense mutations in the DHCR24 gene interfered less than triparanol with the enzyme activity. In fact, in the desmosterolosis patients, the enzyme activities varied from nondetectable to 50% of mean activity [31, 33] . In the present study, users of amiodarone had serum lipids and noncholesterol sterols that resemble the desmosterolosis phenotype where some of the DHCR24 enzyme activity is spared. It is interesting that neither triparanol, mutation in the DHCR24 gene, nor amiodarone seems to affect the DHCR24 activity in the other locations of the cholesterol synthesis pathway. Amiodarone and/or its metabolites interfere with several P450 enzyme activities but not with CYP51A, which is involved in the cholesterol synthesis pathway (see Fig. 1 ).
The clinical relevance of increased serum desmosterol concentration in amiodarone users is unknown. However, triparanol therapy has caused accumulation of desmosterol in liver, spleen, lung, kidney, striated and heart muscle, intestine, and adrenal and fat tissue [36] . The increase in tissue desmosterol-to-cholesterol concentration remained the same as in blood [36] , and thus, the accumulation of desmosterol into tissues was not uncontrollable. The etiopathology of corneal deposits and lens opacities in users of amiodarone is unknown, but in triparanol-induced cataracts in rats, increased concentrations of cholesterol and phospholipids were observed [37] . However, the methods used in that study did not separate desmosterol from cholesterol, and it is thus not excluded that accumulation of desmosterol could have a role in the development of the corneal deposits and lens opacities.
In hepatocytes, amiodarone interferes with cellular metabolism resulting in lipid accumulation and inflammation that may eventuate in the development of NASH (reviewed in ref. 8 ). This raises the question of whether increased desmosterol plays a role in the hepatocyte injury from amiodarone. During triparanol treatment, or in the few cases of desmosterolosis described, hepatic side effects were not reported [29] [30] [31] [32] [33] [34] [35] . In the present study, desmosterol was unrelated to serum ALAT. Thus, whether amiodarone-induced dysregulation in desmosterol metabolism affects hepatocytes remains uncertain.
A major limitation of this study is its crosssectional design and, thus, our inability to directly measure treatment-induced serial changes from baseline in serum lipids and noncholesterol sterols. In addition, the results are descriptive, and thus, the detailed biological mechanisms of the effect of amiodarone on cholesterol synthesis and desmosterol metabolism remain to be investigated in the future. Surprisingly, our patients on amiodarone did not have increased serum cholesterol relative to the group without amiodarone, which at first sight appears to contrast with several earlier works [2] [3] [4] [5] [6] . However, it needs recognition that the drug-related 0.7-1.8 mmol L À1 increase in total cholesterol reported in these works may have resulted from increased desmosterol as the analysis methods did not separate cholesterol and desmosterol [2] [3] [4] [5] . Further, although there are some animal data suggesting that amiodarone reduces the number of LDL receptors [7] , the possible mechanism of amiodarone-induced hypercholesterolaemia in man has, to the best of our knowledge, not been studied hitherto. Thus, whether it is real and how it could come into existence remain unresolved.
In conclusion, use of amiodarone was associated with on average 12-fold serum desmosterol concentrations compared with similar patients not on amiodarone. We propose this results from amiodarone inhibiting the enzymatic conversion of desmosterol to cholesterol. This idea, however, is pending confirmation by methods of basic research. Whether desmosterol accumulation plays a role in amiodarone-related hepatotoxicity needs also to be assessed in future studies.
